Gene therapy for lysosomal storage diseases

This publication has 143 references indexed in Scilit:

• AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis
  Molecular Therapy, 2005
• AAV-Mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy
  Molecular Therapy, 2005
• Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the HumanCLN2cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis
  Human Gene Therapy, 2004
• Recombinant AAV Viral Vectors Pseudotyped with Viral Capsids from Serotypes 1, 2, and 5 Display Differential Efficiency and Cell Tropism after Delivery to Different Regions of the Central Nervous System
  Molecular Therapy, 2004
• AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice
  Molecular Therapy, 2004
• A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
  New England Journal of Medicine, 2003
• Phenotypic rescue after adeno‐associated virus‐mediated delivery of 4‐sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI
  The Journal of Gene Medicine, 2002
• Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors
  Gene Therapy, 2001
• Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's Disease
  New England Journal of Medicine, 1991
• ENZYME REPLACEMENT IN NERVOUS TISSUE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR FUCOSIDOSIS IN DOGS
  The Lancet, 1986